Diagnostic & Therapeutic Guidance for Atopic Dermatitis

The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.

Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.

New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.

Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.